CJC-1295 (No DAC) 10mg – Research Grade Lyophilized Peptide

🧪 Overview

CJC-1295 no DAC is a synthetic peptide analog derived from growth hormone-releasing hormone (GHRH 1–29), developed for laboratory research applications involving endocrine signaling and receptor interaction studies. Unlike its DAC-modified counterpart, CJC-1295 no DAC lacks the Drug Affinity Complex, resulting in a shorter duration of activity and a more transient signaling profile in experimental models.

The peptide is frequently utilized in controlled laboratory environments to study pulsatile signaling patterns, receptor activation, and downstream biochemical cascades associated with GHRH receptor interaction. Its structure is specifically modified to improve stability relative to native GHRH while maintaining a defined and time-dependent activity profile.

Due to these characteristics, CJC-1295 no DAC is particularly relevant for experimental designs that require precise temporal control over peptide-mediated signaling.

---

🔬 Research Context & Mechanism

CJC-1295 no DAC functions as an analog of GHRH, interacting with receptors located on somatotroph cells within the pituitary in experimental models. This interaction initiates signaling cascades associated with growth hormone release, allowing researchers to investigate endocrine pathway regulation and receptor-mediated biochemical responses.

Experimental data has shown that compounds in this class may increase measurable growth hormone and IGF-1 signaling while preserving the natural pulsatility of hormone release.

This preservation of pulsatile signaling makes the peptide particularly useful in laboratory studies examining physiological signaling rhythms, receptor sensitivity, and feedback mechanisms within endocrine systems.

---

🧬 Structural Characteristics

CJC-1295 no DAC is based on the truncated GHRH (1–29) sequence, which represents the minimal functional region of endogenous GHRH. Modifications at specific amino acid positions enhance resistance to enzymatic degradation, allowing for improved stability compared to native peptides.

Unlike DAC-modified variants that bind to serum albumin and extend half-life, CJC-1295 no DAC remains unbound, resulting in a shorter active window. This structural distinction allows researchers to differentiate between sustained versus pulsatile signaling models in controlled experiments.

The absence of DAC is a defining feature that makes CJC-1295 no DAC particularly valuable for studies requiring rapid onset and clearance of signaling activity.

---

🧬 Pharmacological & Biochemical Profile

Within laboratory environments, CJC-1295 no DAC has demonstrated several measurable properties:

• Interaction with GHRH receptors in controlled systems
• Induction of growth hormone-related signaling cascades
• Maintenance of pulsatile signaling behavior
• Shorter duration of activity compared to DAC-modified analogs

Experimental research has shown that CJC-1295 analogs can increase growth hormone and IGF-1 signaling markers following administration in controlled models.

These characteristics make the peptide suitable for studies focused on transient signaling events, receptor activation timing, and endocrine pathway dynamics.

---

🧫 Experimental Applications

CJC-1295 no DAC is commonly utilized in laboratory research involving:

• Growth hormone signaling pathway analysis
• GHRH receptor binding studies
• Endocrine system modeling
• Pulsatile vs sustained signaling comparisons
• Intracellular signaling cascade evaluation

Researchers often employ in vitro systems and controlled experimental models to assess the biochemical activity of CJC-1295 no DAC. Analytical techniques such as receptor binding assays, hormone quantification, and pathway mapping may be used to evaluate signaling responses.

The shorter activity window of CJC-1295 no DAC allows for precise experimental control, making it particularly useful in time-dependent research protocols.

---

📚 Scientific Reference

For further insight into the pharmacological activity of CJC-1295 analogs, refer to the following study:

👉 https://pubmed.ncbi.nlm.nih.gov/17018654/

This study demonstrates that CJC-1295 analogs increase growth hormone and IGF-1 signaling while maintaining natural pulsatility in controlled experimental models.

---

🧊 Handling & Storage

CJC-1295 no DAC is supplied as a lyophilized powder to preserve stability during storage and transport.

Recommended laboratory handling practices include:

• Storage at 2–8°C (36–46°F)
• Use of sterile techniques during preparation
• Reconstitution with analytical-grade solvents
• Avoidance of repeated freeze-thaw cycles

All preparation and handling should follow established laboratory protocols to ensure consistency and experimental integrity.

---

⚠️ Research Use Notice

CJC-1295 no DAC is intended strictly for laboratory research and analytical use. It is not approved for human or veterinary applications. All users are responsible for ensuring compliance with applicable regulations and proper handling procedures.